Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

Alzheimer's Disease

FDA Approves Auvelity, the First Non‑Antipsychotic for Alzheimer’s Agitation

The decision offers an alternative to drugs that carry boxed mortality warnings.

India Approves Donanemab for Early Alzheimer’s as Lilly Targets 2026 Launch

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

France Blocks Early Access to Alzheimer’s Drug Leqembi for Now

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

EMA Recommends Donanemab for Early Alzheimer’s in the EU

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

EU Drug Agency Recommends Approval of First Alzheimer’s Treatment Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs